Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK profiles of LY03010 vs Invega Sustenna in Schizophrenia
NCT04922593Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LY03010 in schizophrenia and schizoaffective disorder (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Relative bioavailability of LY03010 versus INVEGA SUSTENNA at steady-state at Day 176. Started Jan 2021; status: completed.
02
Drugs
LY03010
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT04922593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922593.